CCL2 and Hyperkeratosis: Histological analysis showed that treatment with tangeretin (10 or 39 mg/kg) reduced hyperkeratosis, the influx of inflammatory cells, granulation tissue accumulation, re-epithelialization, and epidermal hyperplasia and, moreover, suppressed serum IgE as well as downregulating the production of IL-1β, IL-6, IL-4, TNF-α, IFN-γ, PGE2, COX-2, macrophage inflammatory protein-2 (MIP-2), monocyte chemoattractant protein-1 (MCP-1), and keratinocyte chemoattractant (KC), which are markers of inflammation.